A recombinant polypeptide and its preparation method

By expressing human type III collagen in Escherichia coli using genetic engineering technology, the problems of infectious disease risk and quality instability in traditional collagen preparation methods have been solved, enabling efficient, safe, large-scale production and the preparation of high-purity recombinant collagen for use in biomedicine and cosmetics.

CN118085064BActive Publication Date: 2024-11-22SHANDONG RONGYUANKANG MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410130401.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-31
Publication Date
2024-11-22
Estimated Expiration
2044-01-31

AI Technical Summary

Technical Problem

Traditional collagen preparation methods rely on animal tissues, which pose risks of infectious disease transmission, unstable quality, low purity, and difficulty in large-scale production.

Method used

Using genetic engineering techniques and synthetic biology tools, recombinant peptides of human type III collagen were designed and expressed in Escherichia coli. The recombinant peptides were then expressed and purified in Escherichia coli Rosetta (DE3) strain using codon-optimized gene sequences to prepare high-purity, biocompatible recombinant collagen.

Benefits of technology

It enables the efficient and safe production of high-purity recombinant collagen, reduces the immunogenicity of animal-derived materials, and possesses good biocompatibility and stability, making it suitable for large-scale production and applicable to the biopharmaceutical and cosmetic industries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118085064B_ABST
    Figure CN118085064B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of genetic engineering technology, and discloses a recombinant polypeptide and a preparation method thereof, wherein the amino acid sequence of the recombinant polypeptide is shown in SEQ ID No. 2, and the fragment is composed of multiple repetitions of the core sequence of human type III collagen. The recombinant collagen polypeptide prepared by the present invention has very good hydrophilicity and stability, and its amino acid composition is 100% identical to the corresponding part of the amino acid sequence of natural collagen, and will not produce immune rejection and allergic reaction when applied to the human body, and has good adhesion activity, and can perform the function of natural protein in the human body to reduce the immunogenicity of collagen from animal sources, and can control the risk of pathogenic virus transmission to a certain extent, and can be widely used in the biomedicine and cosmetics industries.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene engineering technology, in particular to a recombinant polypeptide and a preparation method thereof. Background Art

[0002] Collagen is an important structural protein mainly found in animal tissues, with good biocompatibility and biodegradability. Due to its unique properties, collagen has broad application prospects in many medical and bioengineering fields, such as tissue engineering, biomaterials, and drug sustained release. However, traditional collagen extraction methods are limited by animal-derived materials, and there are problems such as the risk of infectious disease transmission and unstable quality. Therefore, the research and development of an efficient, safe, and stable method for preparing recombinant collagen has important scientific significance and application value.

[0003] Traditional collagen preparation methods mainly rely on the extraction and processing of animal tissues. This method has the following limitations: (1) Animal-derived material limitations: Traditional methods rely on animal tissues, such as skin and bones, to extract collagen. However, animal-derived materials are affected by factors such as animal species and growth environment, resulting in large differences in the quality and performance of collagen. (2) Risk of infectious disease transmission: There are potential infectious disease pathogens in animal tissues, such as viruses and bacteria, and their transmission risks cannot be completely eliminated. (3) Low protein purity: In traditional extraction methods, collagen is often mixed with other tissue components, with low purity, which is difficult to meet the requirements of some specific applications. (4) Unstable quality: Traditional extraction methods are affected by factors such as animal growth environment and diet, resulting in unstable quality and performance of collagen.

[0004] In order to overcome the limitations of traditional collagen preparation methods, it is necessary to develop an efficient, safe and stable recombinant collagen preparation method. This method should have the following characteristics: (1) High purity: The recombinant collagen preparation method should be able to obtain high-purity collagen to meet the needs of different application fields. (2) Controllability: The preparation method should be able to control the structure and properties of recombinant collagen to meet the requirements of specific applications. (3) Biocompatibility: Recombinant collagen should have good biocompatibility to ensure its biosafety in the body. (4) Large-scale production: The preparation method should be scalable and able to meet the needs of large-scale production.

[0005] In recent years, researchers have made significant progress in the study of recombinant collagen polypeptides through genetic engineering technology and biosynthesis methods. These methods use genetic recombination technology and synthetic biology tools to achieve artificial synthesis and expression of collagen polypeptide chains through synthetic gene sequences or biosynthesis pathways. These studies provide new ways for customized production and functional regulation of collagen polypeptides. A common method is to clone the gene sequence of collagen into an expression vector using recombinant DNA technology and express it in an appropriate expression host. Researchers can achieve efficient expression and purification of recombinant collagen polypeptides by optimizing expression conditions, such as selecting suitable host cells, regulating the promoter and regulator of the expression gene, etc. This method can effectively obtain a large amount of high-purity collagen polypeptides, providing a basis for further research and application. Another method is to use synthetic biology tools to synthesize collagen polypeptides through synthetic pathways. Researchers can design and synthesize collagen polypeptides with specific sequences and structures, and synthesize them into chains through chemical synthesis or biosynthesis. This method allows researchers to precisely regulate the structure and function of collagen polypeptides, thereby achieving customization of their biological activity and application performance. Summary of the invention

[0006] 1. Technical issues to be resolved

[0007] In response to the deficiencies in the prior art, the present invention provides a recombinant polypeptide and a method for preparing the same.

[0008] (II) Technical solution

[0009] The amino acid sequence of a recombinant polypeptide is shown in SEQ ID No. 2. The fragment is composed of multiple repeats of the core sequence of human type III collagen, and the basic repeating unit is: GQPGVMGFPGPKGNDGAPGKNGERGGPGGPGPQGPPGKNGETGPQ (SEQ ID No. 1).

[0010] Preferably, the recombinant polypeptide is C1, comprising 360 amino acids, and the amino acid sequence is as follows: GQPGVMGFPGPKGNDGAPGKNGERGGPGGPGPQGPPGKNGETGPQGQPGVMGFPGPKGNDGAPGKNGERGGPGGPGPQGPPGKNGETGPQGQPGVMGFPGPKGNDGAPGKNGERGGPGGPGPQGPPGKNGETGPQGQPGVMGFPGPKGNDGAPGKNGERGGPGGPGPQGPPGKNGETGPQGQPGVMGFPGPKGNDGAPGKNGERGGPGGPGPQGPPGKNGETGPQGQPGVMGFPGPKGNDGAPGKNGERGGPGGPGPQGPPGKNGETGPQGQPGVMGFPGPKGNDGAPGKNGERGGPGGPGPQGPPGKNGETGPQGQPG

[0011]

[0012] Preferably, the nucleotide sequence of the polynucleotide encoding the recombinant polypeptide is shown in SEQ ID No. 3, which is a polynucleotide sequence that can be used for expression in Escherichia coli after codon optimization.

[0013] Preferably, the expression vector comprises the polynucleotide according to claim 2.

[0014] Preferably, the host cell comprises the expression vector according to claim 3.

[0015] Preferably, the host cell is Escherichia coli.

[0016] Preferably, the preparation method of the recombinant polypeptide is as follows:

[0017] (1) codon optimization of amino acids 406-450 in the triple helix region of human type III collagen was performed to obtain the complete target gene by gene synthesis;

[0018] (2) Connecting the target gene to the pET-22b plasmid and transferring it into the Escherichia coli Rosetta (DE3) expression strain to obtain genetically engineered Escherichia coli;

[0019] (3) Cultivating the engineered bacteria in a shake flask or fermenter and expressing the recombinant polypeptide in large quantities;

[0020] (2) harvesting the composition and purifying the polypeptide;

[0021] (3) Freeze-drying the polypeptide or preparing it into a solution.

[0022] Preferably, the composition comprises the recombinant polypeptide according to claim 1.

[0023] Preferably, the composition can be used in medical devices, tissue engineering products, cosmetics or health products.

[0024] Preferably, the recombinant polypeptide is used to promote cell adhesion.

[0025] (III) Beneficial technical effects

[0026] Compared with the prior art, the present invention has the following characteristics:

[0027] (1) The type III collagen sequence selected in the present invention is obtained through screening, analysis and optimization.

[0028] (2) The present invention adopts a relatively mature E. coli expression system, which is suitable for large-scale production and has the characteristics of low cost and high production efficiency. At the same time, the selected gene sequence is codon optimized to further increase the yield of collagen.

[0029] (3) The recombinant collagen polypeptide prepared by the present invention has very good hydrophilicity and stability, and its amino acid composition is 100% identical to the corresponding part of the natural collagen amino acid sequence. It will not cause immune rejection and allergic reactions when applied to the human body, and can be widely used in the biopharmaceutical and cosmetic industries;

[0030] (4) Activity detection surface: The humanized recombinant collagen polypeptide of the present invention has good adhesion activity and can perform the function of natural protein in the human body.

[0031] (5) The present invention can reduce the immunogenicity of collagen from animal sources as much as possible and can control the risk of pathogenic virus transmission to a certain extent. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is the protein electrophoresis diagram after purification of recombinant collagen polypeptide C1.

[0033] Figure 2 This is the result of the cell adhesion activity test of recombinant collagen polypeptide C1. DETAILED DESCRIPTION

[0034] The technical solution of the present invention is further specifically described below through specific embodiments, but the present invention is not limited to these embodiments.

[0035] The invention synthesizes humanized type III recombinant collagen gene and makes it express in Escherichia coli Rosetta (DE3) strain.

[0036] LB medium: 0.5% yeast extract, 1% peptone and 1% sodium chloride (if preparing solid medium, add 1.5% agar before sterilization), autoclave at 115℃ for 30min.

[0037] TB medium: 2.4% yeast extract, 1.2% peptone, 0.4% glycerol, 100 mL potassium phosphate buffer, autoclaved at 115°C for 30 min.

[0038] Example 1: Construction and expression of C1 gene expression vector:

[0039]

[0040] The full length of C1 gene is 1080bp. The sequence was synthesized by a gene synthesis company and connected to the pET22b plasmid using the restriction sites of NcoⅠ and XhoⅠ. The plasmid was transformed into Escherichia coli Rosetta (DE3), and the positive clones were selected using ampicillin sodium and chloramphenicol double resistance-LB plates.

[0041] (2) Pick the positive E. coli clone, culture it in 4 mL LB medium overnight, transfer it at a ratio of 1:100, and culture it in a shake flask at 37°C until the OD600 is 0.4-0.6. Add IPTG at a final concentration of 0.1 mM to induce expression, culture it at 30°C for 20 hours, collect the cells by centrifugation, and store them at -20°C or proceed to the next purification step immediately.

[0042] (3) Wash the mixed bacterial precipitate with physiological saline, resuspend about 400 mL of bacterial solution in 20-30 mL volume, use lysozyme and Triton X-100 to help lyse the bacteria (optional), sonicate the bacteria in an ice-water mixture environment (5 s sonication, 5 s interval, total time 10 min, protection temperature 30°C), centrifuge at 12000 rpm / min for 20 min, and collect the supernatant. At this time, the solution contains a large amount of C-1 recombinant collagen polypeptide.

[0043] (4) The nickel ion affinity column (Ni-NTA His-Bind Resin) was cleaned with lysis buffer, and then the column and C1 solution were mixed and incubated, gently shaken at room temperature or on ice for 30 min, and then loaded onto the column. The impurities were washed with PBS buffer containing 10 mM imidazole, and then the target protein C1 was washed with PBS buffer containing 300 mM imidazole. The obtained product was ultrafiltered, desalted, and lyophilized to a dry powder for later use.

[0044] (5) The purity of the obtained collagen polypeptide was detected by SDS-PAGE. The specific process is as follows: 8 μL of the purified protein solution was taken, 2 μL of protein loading buffer (250 mM Tris-HCl (pH 6.8), 10% SDS, 0.5% bromophenol blue, 50% glycerol, mercaptoethanol) was added, and the solution was placed in boiling water at 100°C for 3 min, and then 10 μL of each well was added to the SDS-PAGE protein gel, and the voltage was 80 V for 2 h, and then the protein was stained with Coomassie brilliant blue staining solution (0.1% Coomassie brilliant blue R-250, 25% isopropanol, 10% glacial acetic acid) for 20 min, and then decolorized with protein decolorizing solution (10% acetic acid, 5% ethanol). Finally, the protein activity was measured by comparing with human natural collagen.

[0045] result:

[0046] Figure 1The electrophoresis diagram showed that C303-1 with an apparent molecular weight of 35.4 kDa was obtained, and the molecular weight corresponded to the polypeptide of the amino acid sequence of SEQ ID No. 2.

[0047] Example 2: Detection of cell adhesion activity of recombinant collagen polypeptide C1

[0048] The activity detection method of collagen polypeptide can refer to the literature Juming Yao, Satoshi Yanagisawa, Tetsuo Asakura, Design, Expression and Characterization of Collagen-Like Proteins Based on the Cell Adhesive and Crosslinking Sequences Derived from Native Collagens, J Biochem. 136, 643-649 (2004). The specific implementation method is as follows:

[0049] (1) Use ultraviolet absorption method to detect the concentration of the protein samples to be tested, including control human collagen polypeptide and recombinant collagen polypeptide C1 sample. Specifically, measure the ultraviolet absorption of the samples at 215nm and 225nm respectively, and calculate the protein concentration using the empirical formula C (ug / mL) = 144X (A215-A225). Note that the test must be performed when A215 < 1.5. The principle of this method is to measure the characteristic absorption of peptide bonds under far-ultraviolet light. It is not affected by the chromophore content, has few interfering substances, is easy to operate, and is suitable for detecting human collagen and its analogs that do not develop color with Coomassie Brilliant Blue. (Reference is Walker JM. The Protein Protocols Handbook, second edition. Humana Press. 43-45.) After the protein concentration is detected, the concentration of all proteins to be tested is adjusted to 0.5 mg / mL with PBS.

[0050] (2) Add 100 μL of various protein solutions and a blank PBS solution as a control to a 96-well plate and incubate at 4°C overnight.

[0051] (3) Wash each well twice with PBS.

[0052] (3) Add 4*10 4 3T3 cells in good culture state were incubated at 37℃ for 25min.

[0053] (4) Wash each well twice with PBS.

[0054] (5) Use CCK8 kit to detect the absorbance at OD450 nm. Based on the value of blank control, the degree of cell adhesion can be calculated. The cell adhesion rate can reflect the activity of collagen polypeptide. The higher the activity of protein, the better the external environment can be provided to cells in a short time, helping cells to adhere to the wall.

[0055] Results Figure 2 .

[0056] Figure 2 The results showed that the recombinant collagen peptide C1 had comparable adhesion activity to commercial human collagen peptide.

[0057] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.

[0058] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A recombinant polypeptide, characterized in that: The amino acid sequence of the recombinant polypeptide is shown in SEQ ID No. 2, and the recombinant polypeptide is composed of multiple repeats of the core sequence of human type III collagen.

2. The polynucleotide encoding the recombinant polypeptide according to claim 1, characterized in that: The polynucleotide is a polynucleotide sequence that can be used for Escherichia coli expression after codon optimization.

3. An expression vector, characterized in that Comprising the polynucleotide of claim 2.

4. A host cell, characterized in that Comprising the expression vector according to claim 3.

5. The host cell according to claim 4, characterized in that: The host cell is Escherichia coli.

6. A recombinant polypeptide according to claim 1, characterized in that: The preparation method of the recombinant polypeptide is as follows: (1) Codon optimization was performed on amino acids 406-450 of the triple helix region of human type III collagen, and the complete target gene was obtained by gene synthesis; (2) Connect the target gene to the pET-22b plasmid and transfer it into the Escherichia coli Rosetta (DE3) expression strain to obtain genetically engineered Escherichia coli; (3) Cultivate the engineered bacteria in a shake flask or fermenter and express the recombinant polypeptide in large quantities; (4) harvesting the composition and purifying the polypeptide; (5) Freeze-drying the peptide or preparing it into a solution.

7. A composition, characterized in that: Comprising the recombinant polypeptide according to claim 1.

8. The composition according to claim 7, characterized in that: The composition is a medical device, a tissue engineering product, a cosmetic or a health product.

9. Use of the recombinant polypeptide according to claim 1 in preparing a product for promoting cell adhesion.

10. Use of the composition according to claim 7 or 8 in the preparation of a product for promoting cell adhesion.